A Phase I, Open-Label, 3-Way Crossover Trial in Healthy Subjects to Compare the Bioavailability of a Single Oral Dose of TMC435350 Formulated as 2 Different Solid Formulations to That of a Single Oral Dose of TMC435350 Formulated as a Powder Blend Capsule.
Phase of Trial: Phase I
Latest Information Update: 21 Oct 2009
At a glance
- Drugs Simeprevir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 18 Apr 2009 Planned number of patients changed from 12 to 24 as reported by ClinicalTrials.gov.
- 18 Apr 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Apr 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.